MedTrace Logo

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

NCT04895293 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-04-12

Study results available
· View outcomes & findings →

Summary

This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

RBM-007 Injectable Solution

Sterile solution

Sponsors & Collaborators

  • Maturi, Raj K., M.D., P.C.

    lead INDIV

Principal Investigators

  • Raj K. Maturi, M.D. · Midwest Eye Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-02-08
Completion
2022-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895293 on ClinicalTrials.gov